Search
Research
Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings.
Research
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.
Research
The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyodermaWe conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
News & Events
Four BrightSpark Fellowships awarded to early-career researchers at The KidsCongratulations to four outstanding early-career researchers from The Kids Research Institute Australia, who have been awarded BrightSpark Foundation fellowships and project funding for 2026.
News & Events
The Kids Research Institute Australia leader named finalist in nation’s top science prizesOne of Australia’s leading infectious disease experts, Associate Professor Asha Bowen, has been announced as a finalist for the country’s leading national science awards – the Australian Museum Eureka Prizes.
Research
Perinatal risk factors associated with skin infection hospitalisation in Western Australian Aboriginal and Non-Aboriginal childrenWe have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
Research
Clinic attendances during the first 12 months of life for Aboriginal children in five remote communities of northern AustraliaThe median number of presentations per child in the first year of life was 21 with multiple reasons for presentation.
Research
Swimming pools in remote Aboriginal communitiesProviding remote communities with access to chlorinated swimming pools has been considered as a possible strategy for reducing ear and skin infection rates...
Research
Berrembi Jarragboo-Boorroo Wajawoorroo Men'Gawoom Gijam (Gija Healthy Skin Story): Two-Way Learning for Healthy SkinRemote-living Aboriginal children in Australia contend with higher rates of skin infections than non-Indigenous children. This work was embedded within a stepped-wedge, cluster randomised controlled trial aiming to halve the rate of skin infections in remote Kimberley communities. It outlines and reflects upon the co-development of a health promotion resource in partnership with the East Kimberley community of Warmun, whilst understanding community perceptions of its impact.